Head-and-neck squamous-cell carcinoma (HNSCC) — a frequent neoantigen-vaccine setting.
January 09, 2026 02:00 ET | Source: Transgene S.A. Transgene S.A. TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 potential as an individualized cancer immunotherapy Strasbourg, Franc…
A new review in Frontiers in Oncology outlines the rationale for combining personalized cancer vaccines with immune checkpoint inhibitors in head and neck squamous cell carcinoma (HNSCC). The authors highlight that while HNSCC presents challenges due to its complex tumor microenvironment and lack of actionable mutations, therapeutic vaccines can enhance innate and adaptive immune responses. This synthesis underscores the clinical momentum toward combination therapies to overcome resistance in this high-burden indication.
Analysis of 527 HNSCC tumors reveals an inverse relationship between neoantigen clonality and T-cell activity, challenging the hypothesis that clonal neoantigens drive exhaustion. Using pVACseq and MHCflurry, the study found that clonal neoantigens correlate with reduced T-cell infiltration and activation signatures, suggesting distinct immune phenotypes that may impact vaccine target selection.
UNC Lineberger Comprehensive Cancer Center has suspended a Phase I trial of the PANDA-VAC personalized neoantigen peptide vaccine administered concurrently with pembrolizumab. The study was designed for advanced squamous NSCLC and head and neck squamous cell carcinoma, assessing safety and dose adjustment protocols.
A Phase I trial of a neoantigen vaccine reported a 100% disease-free survival rate in head and neck squamous cell carcinoma (HNSCC). This outcome underscores the potential for personalized vaccines to achieve durable remission in specific solid tumor indications.